Our health care system is far from perfect, but there are solutions that will help address patient affordability concerns without sacrificing innovation, access or quality of care. For example, biopharmaceutical companies are working with other health care stakeholders to develop new ways to pay for medicines through innovative, results-based contracts that can improve affordability and more tightly link the price of medicines to the outcomes they deliver for patients. Solutions like innovative contracts support continued access and innovation in health care in the United States by building on the current system and strengthening market competition – rather than importing the flawed policies of foreign governments where cutting costs often comes at the expense of patient care quality and choice.
Innovative contracts are flexible payment arrangements between biopharmaceutical companies and insurers that can generally be divided into three categories: (1) results-based contracts, (2) alternative financing arrangements or (3) a hybrid of those two models. To date, insurers and biopharmaceutical companies have announced 75 such partnerships – covering nearly 30 conditions – and their continued use promises to deliver even greater value to the health care system in the future.
- Value-based contracts: Also known as results-based contracts, value-based contracts are agreements between biopharmaceutical companies and payers that link payment for a specific medicine to how well it works for patients, thus balancing risk between innovators and insurers. These agreements can take several forms such as outcomes-, indication- or regimen-based contracts and are designed to help payers control costs while maintaining incentives for biopharmaceutical companies to invest in future research and development for new treatments and cures. Value-based contracts can be beneficial to patients by improving access to medicines and lowering out-of-pocket costs.
- Alternative financing agreements: These include pay-over-time and expenditure caps methods as a way to provide access to new medicines.
-
- Pay-over-time models allow payers to pay for a medicine across an extended period.
- Expenditure caps limit the per-patient cost of a medicine to an agreed-upon threshold. In subscription models, a type of expenditure cap, the potential cost for payers is averaged across the population covered, and payers agree to pay a prospective per member per month cost to buy therapeutic coverage for their members. Under increasingly popular expenditure cap models, such as those used by some states to treat hepatitis C, the payer pays a fixed sum for an unlimited supply of the medicine.
- Pay-over-time models allow payers to pay for a medicine across an extended period.
- Hybrid models: Hybrid approaches combine aspects from value-based contracts and alternative financing agreements, such as when a biopharmaceutical company and payer agree to enter into a contract where payment is issued over time, contingent upon tangible treatment benchmarks.
To learn more visit www.phrma.org/value-collaborative.
Katie Koziara
Katie Koziara is Senior Director of public affairs at PhRMA focusing on the organization’s executive visibility work and media relations strategy. She previously ran the social media strategy for a D.C.-based non-profit working on federal management and leadership issues. Katie earned her B.A. in Public Policy from the University of Michigan’s Ford School and is currently earning her M.A. in Fiction Writing from Johns Hopkins University.
Katie Koziara
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
Three things to know about the United Nations’ new HIV/AIDS report
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
ICYMI: Misaligned policies undermine patient access
3 Takeaways from POLITICO’s Health Care Summit
New analysis of patient access restrictions in the United Kingdom
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
States can support access to medicine as COVID-19 Public Health Emergency ends
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
In their own words: Insured Americans support policy reforms that address access and affordability concerns
CMS coverage decision restricts access to treatments for Alzheimer’s disease
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
PhRMA presents research at ISPOR 2022
Report finds PBMs are increasingly restricting patient access to medicines
Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs
Getting the 340B program back on track in 2021
Growth in innovative, value-based contracts holds promise for the health system and for patients
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
Low-value health care costs $345B each year and provides little benefit
Addressing barriers that inhibit value-based contracts
Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
Setting the record straight on international reference pricing
5 Ways to improve ICER’s value assessment framework
Assessing value top of mind at ISPOR 2019
Fact Check: How the Part B International Pricing Index model threatens patient access
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
Value assessments should include all the outcomes that matter to patients and families
PhRMA comments to administration on Medicare Part D proposed rule
ICYMI: New study reinforces dangers of proposed IPI model
Groups sound the alarm on administration’s new Part B proposal
4 things you need to know about the administration’s latest Part B proposal
PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
Number of value-based contracts continues to rise
How much do you know about Medicare Part B?
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
Event next week: Supporting the next generation of lifesaving medicines
How ICER’s assessment of a new class of migraine treatments fails patients
Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge
Aspen Spotlight Health: Discussing the forefront of innovation
New analysis shows that more medicines worldwide are available to U.S. patients
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches
Event tomorrow: Improving patient access to lifesaving medicines
Event tomorrow: Making the biopharmaceutical supply chain work for patients
Reality check: Value-based contracts are good for patients
Video: Barriers to results-based contracts
PPA celebrates 13 years of helping patients access their medicines
Improving care quality by engaging patients in shared decision making
ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access
Copay coupons can help ease patients’ out-of-pocket costs
PhRMA launches new consumer-facing Let’s Talk About Cost website
Clarity around anti-kickback statute needed to promote innovative payment arrangements
Video: What is a results-based contract?
How much are hospitals marking up the price of medicines? The answer may surprise you.
Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care
Foreign government price setting by any name harms innovation and access to medicines
PhRMA CEO in Forbes - How to negotiate better deals for prescription medicines
Compulsory licensing: A misused and abused international trade law
Government-imposed price controls threaten innovation and access
ICYMI: Innovative payment models helping provide patient access to new medicines
RA medicines often demonstrate far greater benefits to patients than initially understood
Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
How do multiple sclerosis patients define value?
Biopharmaceutical industry’s success reducing disparities for African Americans
Medicare Monday: What is IPAB, and why is it bad for patients?
PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
Innovative contracts drive access for patients and value for the system
Access
The Value Collaborative
Innovative contracts drive access for patients and value for the system
Innovative contracts drive access for patients and value for the system